Baricitinib, Drugs Monitor

(09 May 2021) Baricitinib- daily high dose of baricitinib in severe COVID-19 results in early stabilization of the respiratory functions

May 27, 2021

Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh https://doi.org/10.1186/s12879-021-06119-2 This prospective cohort study was conducted on 238 adult patients with severe COVID-19 pneumonia. Eight milligram and 4 mg of baricitinib was given… Continue reading "(09 May 2021) Baricitinib- daily high dose of baricitinib in severe COVID-19 results in early stabilization of the respiratory functions"

(03 May 2021) Baricitinib- when added to SOC, significantly decreased mortality

May 24, 2021

Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1 NCT04421027- In this phase 3, global, double-blind, randomized, placebo-controlled trial, 1525 hospitalized adults with COVID-19 receiving standard of care (SOC) were randomly assigned (1:1) to once-daily baricitinib 4-mg (N=764)… Continue reading "(03 May 2021) Baricitinib- when added to SOC, significantly decreased mortality"

(29 Dec 2020) Baricitinib- additional loading dose of baricitinib revealed better clinical outcome

January 2, 2021

Additional baricitinib loading dose improves clinical outcome in COVID-19 https://doi.org/10.1515/med-2021-0010 This prospective case-control study enrolled 37 adult patients where 17 patients (control) received baricitinib at 4 mg oral daily dose and 20 patients (case) received an additional single 8 mg… Continue reading "(29 Dec 2020) Baricitinib- additional loading dose of baricitinib revealed better clinical outcome"

(01 July 2020) Baricitinib- 12 out of 15 patients recovered with Baricitinib and HCQ combination

July 6, 2020

Use of Baricitinib in Patients with Moderate and Severe COVID-19 https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/ciaa879/5864596 In this retrospective cohort, 15 patients with moderate-severe COVID-19 were treated with baricitinib and hydroxychloroquine. Twelve of 15 recovered, and 3 died. We observed temporally associated clinical improvement following… Continue reading "(01 July 2020) Baricitinib- 12 out of 15 patients recovered with Baricitinib and HCQ combination"

(29 June 2020) Baricitinib- induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia

June 30, 2020

Baricitinib restrains the immune dysregulation in COVID-19 patients https://doi.org/10.1101/2020.06.26.20135319 Evidences that baricitinib-induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia are provided in this study. A significant reduction in serum levels… Continue reading "(29 June 2020) Baricitinib- induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia"

(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm

June 29, 2020

Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia https://doi.org/10.1016/j.jinf.2020.06.052 113 patients were in the baricitinib-arm, and 78 in the control-arm. The results indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared… Continue reading "(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm"

(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU

April 27, 2020

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/ Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. In baricitinib-treated patients no adverse events were recorded and clinical and respiratory parameters significantly improved… Continue reading "(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU"

Tag: Baricitinib